Rockwell Medical (RMTI) to Release Quarterly Earnings on Thursday

Rockwell Medical (NASDAQ:RMTI) is expected to be issuing its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Rockwell Medical to post earnings of ($0.2350) per share and revenue of $17.82 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 13, 2026 at 8:00 AM ET.

Rockwell Medical Price Performance

Shares of Rockwell Medical stock opened at $7.08 on Wednesday. The business has a 50 day simple moving average of $6.43 and a two-hundred day simple moving average of $8.28. Rockwell Medical has a 12 month low of $4.89 and a 12 month high of $21.00. The stock has a market capitalization of $28.11 million, a P/E ratio of -4.72 and a beta of 1.60. The company has a debt-to-equity ratio of 0.23, a current ratio of 3.74 and a quick ratio of 3.43.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Geode Capital Management LLC lifted its stake in shares of Rockwell Medical by 12.9% in the 4th quarter. Geode Capital Management LLC now owns 364,816 shares of the company’s stock valued at $304,000 after purchasing an additional 41,668 shares during the last quarter. XTX Topco Ltd grew its holdings in shares of Rockwell Medical by 286.5% during the 4th quarter. XTX Topco Ltd now owns 62,097 shares of the company’s stock worth $52,000 after purchasing an additional 46,029 shares during the period. Jane Street Group LLC acquired a new stake in shares of Rockwell Medical during the 4th quarter worth about $84,000. Finally, Vanguard Group Inc. raised its holdings in Rockwell Medical by 12.3% in the 3rd quarter. Vanguard Group Inc. now owns 1,354,147 shares of the company’s stock valued at $1,625,000 after buying an additional 148,737 shares during the period. Institutional investors and hedge funds own 23.31% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on RMTI. Wall Street Zen raised Rockwell Medical to a “hold” rating in a research note on Saturday, July 25th. Weiss Ratings upgraded Rockwell Medical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 6th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price (up from $2.00) on shares of Rockwell Medical in a research note on Thursday, July 9th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $20.00.

Rockwell Medical Company Profile

Rockwell Medical, Inc is a Delaware?domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.